Geron CorpNASDAQ:GERN
- LAST PRICE4.0700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.8100/ 1
- Ask / Lots4.1200/ 8
- Open / Previous Close--- / 4.0700
- Day Range---
- 52 Week Range
- Volume2
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GERN |
|---|---|---|
| 09:32 ET | 107099 | 4.04 |
| 09:33 ET | 12976 | 4.03 |
| 09:35 ET | 8248 | 4.035 |
| 09:37 ET | 29305 | 4.045 |
| 09:39 ET | 9836 | 4.045 |
| 09:42 ET | 60018 | 4.0383 |
| 09:44 ET | 10958 | 4.045 |
| 09:46 ET | 26153 | 4.05 |
| 09:48 ET | 37821 | 4.05 |
| 09:50 ET | 74208 | 4.055 |
| 09:51 ET | 51468 | 4.05 |
| 09:53 ET | 27166 | 4.035 |
| 09:55 ET | 4110 | 4.04 |
| 09:57 ET | 17580 | 4.04 |
| 10:00 ET | 1625 | 4.035 |
| 10:02 ET | 14513 | 4.025 |
| 10:04 ET | 5751 | 4.025 |
| 10:06 ET | 11609 | 4.025 |
| 10:08 ET | 973 | 4.025 |
| 10:09 ET | 26741 | 4.045 |
| 10:11 ET | 36474 | 4.05 |
| 10:13 ET | 5944 | 4.05 |
| 10:15 ET | 18836 | 4.045 |
| 10:18 ET | 9425 | 4.045 |
| 10:20 ET | 14740 | 4.06 |
| 10:22 ET | 43431 | 4.065 |
| 10:24 ET | 24741 | 4.055 |
| 10:26 ET | 44182 | 4.05 |
| 10:27 ET | 10938 | 4.035 |
| 10:29 ET | 11522 | 4.025 |
| 10:31 ET | 7897 | 4.025 |
| 10:33 ET | 5702 | 4.025 |
| 10:36 ET | 24925 | 4.025 |
| 10:38 ET | 18062 | 4.035 |
| 10:40 ET | 1000 | 4.04 |
| 10:42 ET | 1800 | 4.035 |
| 10:44 ET | 18378 | 4.0497 |
| 10:45 ET | 29749 | 4.045 |
| 10:47 ET | 2348 | 4.045 |
| 10:49 ET | 5600 | 4.04 |
| 10:51 ET | 17000 | 4.035 |
| 10:54 ET | 6359 | 4.035 |
| 10:56 ET | 10926 | 4.0329 |
| 10:58 ET | 15557 | 4.045 |
| 11:00 ET | 500 | 4.05 |
| 11:02 ET | 6546 | 4.05 |
| 11:03 ET | 5885 | 4.05 |
| 11:05 ET | 9958 | 4.045 |
| 11:07 ET | 11844 | 4.045 |
| 11:09 ET | 7545 | 4.045 |
| 11:12 ET | 97510 | 4.045 |
| 11:14 ET | 55401 | 4.045 |
| 11:16 ET | 5579 | 4.05 |
| 11:18 ET | 10689 | 4.045 |
| 11:20 ET | 93871 | 4.045 |
| 11:21 ET | 315142 | 4.05 |
| 11:23 ET | 662704 | 4.065 |
| 11:25 ET | 63095 | 4.08 |
| 11:27 ET | 16081 | 4.075 |
| 11:30 ET | 95102 | 4.085 |
| 11:32 ET | 31816 | 4.09 |
| 11:34 ET | 73379 | 4.095 |
| 11:36 ET | 17215 | 4.095 |
| 11:38 ET | 182547 | 4.1 |
| 11:39 ET | 36296 | 4.1 |
| 11:41 ET | 15546 | 4.095 |
| 11:43 ET | 24494 | 4.1 |
| 11:45 ET | 226398 | 4.085 |
| 11:48 ET | 9814 | 4.09 |
| 11:50 ET | 7313 | 4.085 |
| 11:52 ET | 11545 | 4.09 |
| 11:54 ET | 49066 | 4.1 |
| 11:56 ET | 48048 | 4.1 |
| 11:57 ET | 43477 | 4.1 |
| 11:59 ET | 11300 | 4.1 |
| 12:01 ET | 19333 | 4.095 |
| 12:03 ET | 2800 | 4.1 |
| 12:06 ET | 3685 | 4.1 |
| 12:08 ET | 56440 | 4.0799 |
| 12:10 ET | 50993 | 4.095 |
| 12:12 ET | 1700 | 4.095 |
| 12:14 ET | 30171 | 4.095 |
| 12:15 ET | 1616 | 4.0911 |
| 12:17 ET | 7326 | 4.1 |
| 12:19 ET | 1912 | 4.095 |
| 12:21 ET | 2415 | 4.095 |
| 12:24 ET | 521 | 4.095 |
| 12:26 ET | 1149 | 4.0988 |
| 12:28 ET | 6200 | 4.1 |
| 12:30 ET | 25401 | 4.095 |
| 12:32 ET | 23445 | 4.085 |
| 12:33 ET | 7000 | 4.085 |
| 12:35 ET | 39933 | 4.085 |
| 12:37 ET | 7463 | 4.085 |
| 12:39 ET | 2999 | 4.0821 |
| 12:42 ET | 344 | 4.085 |
| 12:44 ET | 38551 | 4.0896 |
| 12:46 ET | 181043 | 4.085 |
| 12:48 ET | 102087 | 4.1 |
| 12:50 ET | 2120 | 4.0941 |
| 12:51 ET | 5000 | 4.095 |
| 12:53 ET | 3654 | 4.095 |
| 12:55 ET | 586 | 4.095 |
| 12:57 ET | 1821 | 4.095 |
| 01:00 ET | 1669 | 4.095 |
| 01:02 ET | 1872 | 4.095 |
| 01:04 ET | 18858 | 4.095 |
| 01:06 ET | 5311 | 4.095 |
| 01:08 ET | 2100 | 4.1 |
| 01:09 ET | 2800 | 4.095 |
| 01:11 ET | 2798 | 4.1 |
| 01:13 ET | 11735 | 4.095 |
| 01:15 ET | 2308 | 4.095 |
| 01:18 ET | 4230 | 4.095 |
| 01:20 ET | 3633 | 4.095 |
| 01:22 ET | 3132 | 4.095 |
| 01:24 ET | 500 | 4.095 |
| 01:26 ET | 31510 | 4.085 |
| 01:27 ET | 3587 | 4.085 |
| 01:29 ET | 2600 | 4.085 |
| 01:31 ET | 2710 | 4.085 |
| 01:33 ET | 600 | 4.09 |
| 01:36 ET | 7794 | 4.09 |
| 01:38 ET | 16491 | 4.095 |
| 01:40 ET | 109292 | 4.085 |
| 01:42 ET | 6800 | 4.085 |
| 01:44 ET | 4695 | 4.09 |
| 01:45 ET | 4671 | 4.09 |
| 01:47 ET | 36568 | 4.075 |
| 01:49 ET | 20919 | 4.075 |
| 01:51 ET | 8245 | 4.075 |
| 01:54 ET | 31269 | 4.065 |
| 01:56 ET | 6409 | 4.0692 |
| 01:58 ET | 39761 | 4.075 |
| 02:00 ET | 29563 | 4.085 |
| 02:02 ET | 6356 | 4.09 |
| 02:03 ET | 14534 | 4.09 |
| 02:05 ET | 4995 | 4.09 |
| 02:07 ET | 2795 | 4.09 |
| 02:09 ET | 47401 | 4.09 |
| 02:12 ET | 13009 | 4.09 |
| 02:14 ET | 9159 | 4.09 |
| 02:16 ET | 8381 | 4.09 |
| 02:18 ET | 6000 | 4.09 |
| 02:20 ET | 45176 | 4.095 |
| 02:21 ET | 75311 | 4.08 |
| 02:23 ET | 5040 | 4.085 |
| 02:25 ET | 1912 | 4.085 |
| 02:27 ET | 137087 | 4.0869 |
| 02:30 ET | 10204 | 4.085 |
| 02:32 ET | 43839 | 4.085 |
| 02:34 ET | 49271 | 4.095 |
| 02:36 ET | 21638 | 4.095 |
| 02:38 ET | 8000 | 4.095 |
| 02:39 ET | 5896 | 4.095 |
| 02:41 ET | 8783 | 4.095 |
| 02:43 ET | 15655 | 4.09 |
| 02:45 ET | 46164 | 4.085 |
| 02:48 ET | 93754 | 4.07 |
| 02:50 ET | 9197 | 4.075 |
| 02:52 ET | 46448 | 4.075 |
| 02:54 ET | 5632 | 4.07 |
| 02:56 ET | 3865 | 4.075 |
| 02:57 ET | 7661 | 4.07 |
| 02:59 ET | 14955 | 4.075 |
| 03:01 ET | 12367 | 4.075 |
| 03:03 ET | 8692 | 4.075 |
| 03:06 ET | 32784 | 4.065 |
| 03:08 ET | 4755 | 4.065 |
| 03:10 ET | 6843 | 4.065 |
| 03:12 ET | 2963 | 4.065 |
| 03:14 ET | 35235 | 4.0692 |
| 03:15 ET | 4897 | 4.065 |
| 03:17 ET | 8535 | 4.065 |
| 03:19 ET | 1045 | 4.065 |
| 03:21 ET | 5773 | 4.07 |
| 03:24 ET | 3640 | 4.07 |
| 03:26 ET | 2950 | 4.07 |
| 03:28 ET | 5195 | 4.0689 |
| 03:30 ET | 4518 | 4.07 |
| 03:32 ET | 25740 | 4.065 |
| 03:33 ET | 9150 | 4.065 |
| 03:35 ET | 6005 | 4.065 |
| 03:37 ET | 3943 | 4.065 |
| 03:39 ET | 9290 | 4.065 |
| 03:42 ET | 11472 | 4.065 |
| 03:44 ET | 4426 | 4.065 |
| 03:46 ET | 50547 | 4.065 |
| 03:48 ET | 4224 | 4.065 |
| 03:50 ET | 12456 | 4.065 |
| 03:51 ET | 42599 | 4.07 |
| 03:53 ET | 66339 | 4.08 |
| 03:55 ET | 47920 | 4.075 |
| 03:57 ET | 145901 | 4.07 |
| 04:00 ET | 883567 | 4.07 |
Nov 21, 2024
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Thursday Nov 21, 2024 by Dow Jones
4:30PM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 11, 2024
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, from 4:30PM ET on Monday Nov 11, 2024 by Dow Jones
4:30PM ET on Monday Nov 11, 2024 by Dow JonesGeron to Participate in the Stifel 2024 Healthcare Conference, from 9:00AM ET on Monday Nov 11, 2024 by Dow Jones
9:00AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 7, 2024
Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million, from 7:10AM ET on Thursday Nov 07, 2024 by Dow Jones
7:10AM ET on Thursday Nov 07, 2024 by Dow JonesGeron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors, from 7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Geron Corp | 2.5B | -12.6x | --- |
Belite Bio Inc | 2.5B | -72.4x | --- |
Soleno Therapeutics Inc | 2.5B | -17.4x | --- |
Apogee Therapeutics Inc | 2.5B | -16.3x | --- |
Longboard Pharmaceuticals Inc | 2.3B | -26.7x | --- |
Iovance Biotherapeutics Inc | 2.6B | -5.7x | --- |
Company Information
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Contact Information
- Headquarters
- 919 East Hillsdale Boulevard, Suite 250FOSTER CITY, CA, United States 94404
- Phone
- 650-473-7700
- Fax
- 302-655-5049
Executives
- Chairman of the Board, President, Chief Executive Officer
- John Scarlett
- Chief Financial Officer, Executive Vice President - Finance, Treasurer
- Michelle Robertson
- Executive Vice President, Chief Operating Officer
- Andrew Grethlein
- Chief People Officer, Senior Vice President
- Shannon Odam
- Executive Vice President, Chief Legal Officer, Secretary
- Scott Samuels
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5B |
|---|---|
Revenue (TTM) | $29.5M |
Shares Outstanding | 604.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.51 |
EPS | $-0.32 |
Book Value | $0.46 |
P/E Ratio | -12.6x |
Price/Sales (TTM) | 83.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -705.46% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
